Ozenoxacin: A Novel Topical Antibiotic

Overview

Journal Indian J Dermatol Venereol Leprol

Specialties Dermatology
Infectious Diseases
Tropical Medicine

Date 2021 Feb 13

PMID 33580932

Citations 1

Authors

Parvathy Santhosh

Mithun Harold Thomas

Affiliations

Soon will be listed here.

Citing Articles

Polypharmacology: promises and new drugs in 2022.

Ryszkiewicz P, Malinowska B, Schlicker E Pharmacol Rep. 2023; 75(4):755-770.

PMID: 37278927 PMC: 10243259. DOI: 10.1007/s43440-023-00501-4.

References

Brown J, Shriner D, Schwartz R, Janniger C . Impetigo: an update. Int J Dermatol. 2003; 42(4):251-5. DOI: 10.1046/j.1365-4362.2003.01647.x. View

Nagabushan H . Retapamulin: a novel topical antibiotic. Indian J Dermatol Venereol Leprol. 2010; 76(1):77-9. DOI: 10.4103/0378-6323.58693. View

Fernandes P . Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections. Cold Spring Harb Perspect Med. 2016; 6(1):a025437. PMC: 4691801. DOI: 10.1101/cshperspect.a025437. View

Bastos M, Mondino P, Azevedo M, Santos K, Giambiagi-deMarval M . Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin. Eur J Clin Microbiol Infect Dis. 1999; 18(6):393-8. DOI: 10.1007/s100960050306. View

Poovelikunnel T, Gethin G, Humphreys H . Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother. 2015; 70(10):2681-92. DOI: 10.1093/jac/dkv169. View

Babu T, Rekasius V, Parada J, Schreckenberger P, Challapalli M . Mupirocin resistance among methicillin-resistant Staphylococcus aureus-colonized patients at admission to a tertiary care medical center. J Clin Microbiol. 2009; 47(7):2279-80. PMC: 2708468. DOI: 10.1128/JCM.01834-08. View

11.

Sahu J, Mishra A . Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo. Curr Drug Discov Technol. 2018; 16(3):259-264. DOI: 10.2174/1570163815666180502165014. View

12.

Lopez Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Canton R . In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria. Antimicrob Agents Chemother. 2013; 57(12):6389-92. PMC: 3837899. DOI: 10.1128/AAC.01509-13. View

13.

Fabrega A, Madurga S, Giralt E, Vila J . Mechanism of action of and resistance to quinolones. Microb Biotechnol. 2011; 2(1):40-61. PMC: 3815421. DOI: 10.1111/j.1751-7915.2008.00063.x. View

14.

Ashley R, Dittmore A, McPherson S, Turnbough Jr C, Neuman K, Osheroff N . Activities of gyrase and topoisomerase IV on positively supercoiled DNA. Nucleic Acids Res. 2017; 45(16):9611-9624. PMC: 5766186. DOI: 10.1093/nar/gkx649. View

15.

Drlica K, Zhao X . DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997; 61(3):377-92. PMC: 232616. DOI: 10.1128/mmbr.61.3.377-392.1997. View

17.

Takei M, Fukuda H, Kishii R, Hosaka M . Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001; 45(12):3544-7. PMC: 90866. DOI: 10.1128/AAC.45.12.3544-3547.2001. View

18.

Vila J, Hebert A, Torrelo A, Lopez Y, Tato M, Garcia-Castillo M . Ozenoxacin: a review of preclinical and clinical efficacy. Expert Rev Anti Infect Ther. 2019; 17(3):159-168. DOI: 10.1080/14787210.2019.1573671. View

19.

Wren C, Bell E, Eiland L . Ozenoxacin: A Novel Topical Quinolone for Impetigo. Ann Pharmacother. 2018; 52(12):1233-1237. DOI: 10.1177/1060028018786510. View

20.

Yamakawa T, Mitsuyama J, Hayashi K . In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002; 49(3):455-65. DOI: 10.1093/jac/49.3.455. View

21.

Canton R, Morrissey I, Vila J, Tato M, Garcia-Castillo M, Lopez Y . Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates. Future Microbiol. 2018; 13:3-19. DOI: 10.2217/fmb-2017-0289. View

22.

Gropper S, Albareda N, Chelius K, Kruger D, Mitha I, Vahed Y . Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiol. 2014; 9(9):1013-23. DOI: 10.2217/fmb.14.78. View

24.

Tarrago C, Esquirol L, Arano A, Lachamp L, DAniello F, Zsolt I . Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus. Future Microbiol. 2018; 13:21-30. DOI: 10.2217/fmb-2017-0290. View

27.

Costa S, Viveiros M, Rosato A, Melo-Cristino J, Couto I . Impact of efflux in the development of multidrug resistance phenotypes in Staphylococcus aureus. BMC Microbiol. 2015; 15:232. PMC: 4619429. DOI: 10.1186/s12866-015-0572-8. View

28.

Gropper S, Albareda N, Santos B, Febbraro S . Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers. Future Microbiol. 2014; 9(8 Suppl):S11-6. DOI: 10.2217/fmb.14.82. View